Ultragenyx Pharmaceutical (RARE) logo

RARE earnings date, and what happened the last 4 times

Next report

Tue Nov 3

Quality Score today -2

After the close, in 8 days. Expected: the company has not confirmed it.

RARE closed higher after 1 of its last 4 reports. On average it closed -3.6% the session after a report.

The moment RARE reports

  • Its figures, in plain words
  • How it moves after, beside its last four
  • Its Quality Score going in, and after
Get an alert when RARE reports, with its figures

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

What happened after RARE's last 4 reports

RARE's last 4 earnings reports
ReportedScore
going in
GapReaction
Aug 4, 20262026 · After close2estimated+10.3%-3.4%
May 5, 20262026 · After close1estimated+3.6%+3.7%
Feb 12, 20262026 · After close-2estimated-8.3%-12.7%
Nov 4, 20252025 · After close-3estimated-11.0%-1.8%
  • Aug 4, 2026, after the close: the next session RARE opened +10.3% and closed -3.4%, and five sessions on it stood +4.5%. Its Quality Score going in was 2 (Below Average), estimated.
  • May 5, 2026, after the close: the next session RARE opened +3.6% and closed +3.7%, and five sessions on it stood +7.3%. Its Quality Score going in was 1 (Below Average), estimated.
  • Feb 12, 2026, after the close: the next session RARE opened -8.3% and closed -12.7%, and five sessions on it stood -3.3%. Its Quality Score going in was -2 (Poor), estimated.
  • Nov 4, 2025, after the close: the next session RARE opened -11.0% and closed -1.8%, and five sessions on it stood +2.4%. Its Quality Score going in was -3 (Poor), estimated.

Across these 4 reports RARE opened higher after 2 of 4 and closed higher after 1 of 4; on average it opened -1.3%, closed -3.6%, and stood +2.7% five sessions on. Its Quality Score is -2 today, against 2 going into its Aug 4, 2026 report.

Gap: where the stock opened the session after the report. Reaction: where that session closed. Both against the close before the report. The largest of the 4: -12.7% after the Feb 12, 2026 report. A score marked estimated was worked out afterwards from that day's prices and filings; Breakaway has recorded every score live since Sep 9 2026.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Pro members see RARE's reaction live as a report comes out, the release's figures, and an optional alert before it reports.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Questions about RARE's earnings

As of Oct 26, 2026: Ultragenyx Pharmaceutical (RARE): expected to report Tue Nov 3, after the close. RARE closed higher after 1 of its last 4 reports. Its Quality Score is -2 (Poor). Scores as of 10:16 PM ET, 15 minutes behind.

When is RARE's next earnings date?

Expected to report Tue Nov 3, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. RARE closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Does RARE report before or after the market?

RARE is expected to report Tue Nov 3, after the close. Its last 4 reports came after the close.

How did RARE stock react to its last earnings report?

Aug 4, 2026, after the close: the next session RARE opened +10.3% and closed -3.4%, and five sessions on it stood +4.5%.

Does RARE stock usually go up after earnings?

RARE closed higher after 1 of its last 4 reports. On average it closed -3.6% the session after a report, after opening -1.3%. Past behavior, not a forecast.

Ultragenyx Pharmaceutical's page has its Quality Score, its chart, and its insiders' trades. Everyone reporting beside it: next week's earnings.

Past behavior, not a forecast. The score is delayed at least 15 minutes; the reports' moves are as they closed.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.